OnKure Therapeutics, Inc. (OKUR) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, OnKure Therapeutics reported revenue of $0. Net income was -$59.5M, or -$4.40 per diluted share. Operating activities generated -$51.8M of cash, leaving -$51.9M of free cash flow. At fiscal year end, OnKure Therapeutics held $62.1M in total assets against $5.9M in total liabilities, including $59.0M of cash and equivalents.
Open the full interactive OnKure Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
OnKure Therapeutics Key Stats
| Share Price | $2.35 |
|---|---|
| Market Cap | $116.9M |
| 52-Week Range | $2.30 – $5.27 |
| Shares Outstanding | 49.9 million (basic, 2026 Q2) |
OnKure Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$39.8M | -$53.8M | -$83.1M | -$54.4M | -$63.0M |
| Pre-Tax Income | -$39.8M | -$52.0M | -$77.4M | -$52.7M | -$59.5M |
| Income Tax | $0 | $0 | $0 | — | $0 |
| Net Income | -$39.8M | -$52.0M | -$77.4M | -$52.7M | -$59.5M |
| Diluted EPS | -$21.90 | -$21.20 | -$25.20 | -$15.28 | -$4.40 |
OnKure Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$14.7M | -$13.5M | -$15.2M | -$15.3M |
| Diluted EPS | -$1.09 | -$1.00 | -$1.11 | -$0.31 |
OnKure Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $124.7M | $19.9M | $27.6M | $110.8M | $59.0M |
| Current Assets | $153.7M | $106.4M | $106.6M | $113.0M | $60.8M |
| Total Assets | $154.0M | $108.2M | $107.4M | $114.9M | $62.1M |
| Current Liabilities | $6.2M | $7.1M | $18.2M | $10.5M | $5.9M |
| Total Liabilities | $6.8M | $8.2M | $18.8M | $11.1M | $5.9M |
| Shareholders' Equity | $147.2M | $100.0M | $88.6M | $103.8M | $56.2M |
OnKure Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$38.0M | -$47.4M | -$63.7M | -$51.1M | -$51.8M |
| Cash From Investing | -$23.4M | -$57.8M | $10.5M | $15.9M | -$46,000 |
| Cash From Financing | $132.4M | $471,000 | $60.9M | $116.1M | $163,000 |
| Free Cash Flow | -$38.2M | -$47.7M | -$63.9M | -$51.2M | -$51.9M |
Figures from OnKure Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full OnKure Therapeutics financials page for every line item.
OnKure Therapeutics Company Profile
| Ticker | OKUR |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Boulder, Colorado |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001637715 |
Frequently Asked Questions
What was OnKure Therapeutics' revenue in fiscal 2025?
OnKure Therapeutics (OKUR) reported revenue of $0 for fiscal 2025.
What is OnKure Therapeutics' annual revenue history?
OnKure Therapeutics' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was OnKure Therapeutics' net income in fiscal 2025?
OnKure Therapeutics reported net income of -$59.5M for fiscal 2025.
What was OnKure Therapeutics' earnings per share (EPS) in fiscal 2025?
OnKure Therapeutics' diluted EPS was -$4.40 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did OnKure Therapeutics generate in fiscal 2025?
OnKure Therapeutics generated -$51.9M of free cash flow in fiscal 2025.
What was OnKure Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), OnKure Therapeutics reported revenue of $0.
How many shares of OnKure Therapeutics are outstanding?
OnKure Therapeutics reported a weighted average of 49.9 million basic shares outstanding in 2026 Q2.
What is OnKure Therapeutics' market cap?
Based on its latest closing price, OnKure Therapeutics (OKUR) has a market capitalization of about $116.9M.
When does OnKure Therapeutics' fiscal year end?
OnKure Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is OnKure Therapeutics headquartered?
OnKure Therapeutics lists its business address in Boulder, Colorado in its SEC filings.